Anti-Aβ antibodies incapable of reducing cerebral Aβ oligomers fail to attenuate spatial reference memory deficits in J20 mice

Neurobiology of Disease

Volumn 82, Issue , 2015, Pages 372-384

  Mably, Alexandra J ^a   Liu, Wen ^a   Mc Donald, Jessica M ^a   Dodart, Jean Cosme ^b   Bard, Frédérique ^c   Lemere, Cynthia A ^a   O'Nuallain, Brian ^a   Walsh, Dominic M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b The Harvard Center for Neurodegeneration & Repair   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Alzheimer's disease; Amyloid protein; APP transgenic mice; Immunotherapy; Oligomers

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID PRECURSOR PROTEIN; OLIGOMER; TAU PROTEIN; ANTIBODY; NOOTROPIC AGENT;

AMNESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; BRAIN LEVEL; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIPPOCAMPUS; MALE; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN TARGETING; REFERENCE MEMORY; SPATIAL MEMORY; ANIMAL; BLOOD; BRAIN; C57BL MOUSE; DBA MOUSE; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MAZE TEST; MEMORY DISORDERS; METABOLISM; PARENTERAL DRUG ADMINISTRATION; PASSIVE IMMUNIZATION; PHYSIOLOGY; TRANSGENIC MOUSE;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES; BRAIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOHISTOCHEMISTRY; INFUSIONS, PARENTERAL; MALE; MAZE LEARNING; MEMORY DISORDERS; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, TRANSGENIC; NOOTROPIC AGENTS; SPATIAL MEMORY;

EID: 84939243921     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.07.008     Document Type: Article

References (91)

1. Adolfsson O., et al. An effector-reduced anti-beta-amyloid (Abeta) antibody with unique Abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J. Neurosci. 2012, 32:9677-9689.
2. Bales K.R., et al. Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-Abeta antibody. J. Clin. Invest. 2006, 116:825-832.
3. Bard F., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000, 6:916-919.
4. Basi G.S., et al. Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease. J. Biol. Chem. 2010, 285:3417-3427.
5. Benilova I., et al. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 2012, 15:349-357.
6. Biogen-Idec Biogen Idec 2014 revenues increase 40% to $9.7 billion (accessed February 12th 2015). http://www.biogenidec.com/press_release_details.aspx?ID=14712&M=News&PID=61997&NewsID=2459.
7. Blennow K., et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch. Neurol. 2012, 69:1002-1010.
8. Bohrmann B., et al. Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J. Alzheimers Dis. 2012, 28:49-69.
9. Born H.A., et al. Genetic suppression of transgenic APP rescues hypersynchronous network activity in a mouse model of Alzheimer's disease. J. Neurosci. 2014, 34:3826-3840.
10. Burbach G.J., et al. Vessel ultrastructure in APP23 transgenic mice after passive anti-Abeta immunotherapy and subsequent intracerebral hemorrhage. Neurobiol. Aging 2007, 28:202-212.
11. Bussiere T. BIIB037: a fully-human monoclonal antibody that binds specifically to fibrillar abeta, and reduces amyloid burden without affecting vascular amyloid. 11th International Conference on Alzheimer's and Parkinson's Diseases 2013.
12. Bussiere T., et al. Differential in vitro and in vivo binding profiles of BIIB037 and other anti-abeta clinical antibody candidates. 11th International Conference on Alzheimer's and Parkinson's Diseases 2013.
13. Chen C. Biogen will push Alzheimer's drug to phase 3 (accessed February 12th 2015). http://www.bloomberg.com/news/articles/2014-12-02/biogen-rises-on-results-of-early-stage-alzheimer-s-drug-trial.
14. Cheng I.H., et al. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem. 2007, 282:23818-23828.
15. Chin J., et al. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 2005, 25:9694-9703.
16. clinicaltrials.gov Clinical trial of solanezumab for older individuals who may be at risk for memory loss (A4) (accessed February 12th 2015). https://clinicaltrials.gov/ct2/show/NCT02008357.
17. clinicaltrials.gov Dominantly inherited Alzheimer network trial: an opportunity to prevent dementia. a study of potential disease modifying treatments in individuals at risk for or with a type of early onset Alzheimer's disease caused by a genetic mutation (DIAN-TU) accessed February 12th 2015. https://clinicaltrials.gov/ct2/show/NCT01760005.
18. clinicaltrials.gov A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer disease, including a placebo-treated noncarrier cohort (accessed February 12th 2015). https://clinicaltrials.gov/ct2/show/NCT01998841.
19. clinicaltrials.gov A study to evaluate safety, tolerability, and efficacy of BAN2401 in subjects with early Alzheimer's disease (accessed February 12th 2015). https://clinicaltrials.gov/ct2/show/NCT01767311.
20. DeMattos R.B., et al. Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8850-8855.
21. DeMattos R.B., et al. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002, 295:2264-2267.
22. DeMattos R.B., et al. In vitro and in vivo characterization of beta-amyloid antibodies binding to cerebral amyloid angiopathy (CAA) and selective exacerbation of CAA-associated microhemorrhage. Neurobiol. Aging 2004, 25(S2):577.
23. Dillon G.M., et al. Excitotoxic lesions restricted to the dorsal CA1 field of the hippocampus impair spatial memory and extinction learning in C57BL/6 mice. Neurobiol. Learn. Mem. 2008, 90:426-433.
24. Dodart J.C., et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 2002, 5:452-457.
25. Doody R.S., et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 2014, 370:311-321.
26. Dorostkar M.M., et al. Immunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer's disease mouse model. Brain 2014, 137:3319-3326.
27. Farlow M., et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 2012, 8:261-271.
28. Games D., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995, 373:523-527.
29. Hilbich C., et al. Amyloid-like properties of peptides flanking the epitope of amyloid precursor protein-specific monoclonal antibody 22C11. J. Biol. Chem. 1993, 268:26571-26577.
30. Hodges H. Maze procedures: the radial-arm and water maze compared. Brain Res. Cogn. Brain Res. 1996, 3:167-181.
31. Hsia A.Y., et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:3228-3233.
32. Johnson-Wood K., et al. Amyloid precursor protein processing and Abeta42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:1550-1555.
33. Karl T., et al. Cognitive phenotyping of amyloid precursor protein transgenic J20 mice. Behav. Brain Res. 2012, 228:392-397.
34. Karlnoski R.A., et al. Deglycosylated anti-Abeta antibody dose-response effects on pathology and memory in APP transgenic mice. J Neuroimmune Pharmacol. 2008, 3:187-197.
35. Kim J., et al. Normal cognition in transgenic BRI2-Abeta mice. Mol. Neurodegener. 2013, 8:15.
36. Kim W.S., et al. Deletion of Abca7 increases cerebral amyloid-beta accumulation in the J20 mouse model of Alzheimer's disease. J. Neurosci. 2013, 33:4387-4394.
37. Kornecook T.J., et al. Isoform-specific effects of apolipoprotein E on cognitive performance in targeted-replacement mice overexpressing human APP. Genes Brain Behav. 2010, 9:182-192.
38. Kotilinek L.A., et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 2002, 22:6331-6335.
39. Lalonde R., et al. Neurologic and motor dysfunctions in APP transgenic mice. Rev. Neurosci. 2012, 23:363-379.
40. Lannfelt L., et al. Perspectives on future Alzheimer therapies: amyloid-beta protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease. Alzheimers Res. Ther. 2014, 6:16.
41. Lee E.B., et al. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J. Biol. Chem. 2006, 281:4292-4299.
42. Levites Y., et al. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J. Clin. Invest. 2006, 116:193-201.
43. Lord A., et al. An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 2009, 36:425-434.
44. Mably A.J., et al. Tau immunization: a cautionary tale?. Neurobiol. Aging 2015, 36:1316-1332.
45. Maier M., et al. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J. Neurosci. 2006, 26:4717-4728.
46. Mathews P.M., et al. Calpain activity regulates the cell surface distribution of amyloid precursor protein. Inhibition of calpains enhances endosomal generation of beta-cleaved C-terminal APP fragments. J. Biol. Chem. 2002, 277:36415-36424.
47. Mc Donald J.M., et al. The aqueous phase of Alzheimer's disease brain contains assemblies built from approximately 4 and approximately 7kDa Abeta species. Alzheimers Dement. 2015, (in press). 10.1016/j.jalz.2015.01.005.
48. McDonald J.M., et al. The levels of water-soluble and triton-soluble Abeta are increased in Alzheimer's disease brain. Brain Res. 2012, 1450:138-147.
49. Mercken M., et al. Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes. Acta Neuropathol. 1992, 84:265-272.
50. Morgan D., et al. Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
51. Mucke L., et al. High-level neuronal expression of Abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000, 20:4050-4058.
52. Oddo S., et al. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem. 2006, 281:39413-39423.
53. O'Nuallain B., et al. Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J. Neurosci. 2010, 30:14411-14419.
54. O'Nuallain B., et al. A monoclonal antibody against synthetic Abeta dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting Abeta. J. Neurochem. 2011, 119:189-201.
55. O'Nuallain B., et al. Are anti-Abeta aggregate-preferring antibodies the future for AD immunotherapy?. Alzheimers Dement. 2014, 10:P881-P882.
56. Palop J.J., et al. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:9572-9577.
57. Palop J.J., et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007, 55:697-711.
58. Pardridge W.M. Drug targeting to the brain. Pharm. Res. 2007, 24:1733-1744.
59. Pfeifer M., et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002, 298:1379.
60. Racke M.M., et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci. 2005, 25:629-636.
61. Rasool S., et al. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Abeta deposition and tau pathology in 3xTg-AD mice. J. Neurochem. 2013, 126:473-482.
62. Reeves J.P., et al. Mouse monoclonal antibodies to human immunodeficiency virus glycoprotein 120 generated by repeated immunization with glycoprotein 120 from a single isolate, or by sequential immunization with glycoprotein 120 from three isolates. Hybridoma 1995, 14:235-242.
63. Roberson E.D., et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
64. Roberson E.D., et al. Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci. 2011, 31:700-711.
65. Rodgers S.P., et al. Transgenic APP expression during postnatal development causes persistent locomotor hyperactivity in the adult. Mol. Neurodegener. 2012, 7:28.
66. Salloway S., et al. A randomized, double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with mild to moderate Alzheimer's disease who are apolipoprotein E ε4 non-carriers http://www2.kenes.com/efns/info/Documents/Salloway_Bapineuzumab%20IV%20Study%20301_EFNS%20Presentation%20Slides_9-11-2012.pdf.
67. Salloway S., et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 2014, 370:322-333.
68. Sanchez P.E., et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E2895-E2903.
69. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci. 2002, 3:824-828.
70. Schenk D., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
71. Schroeter S., et al. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J. Neurosci. 2008, 28:6787-6793.
72. Seabrook T.J., et al. Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice. Neurobiol. Aging 2007, 28:813-823.
73. Selkoe D.J. The therapeutics of Alzheimer's disease: where we stand and where we are heading. Ann. Neurol. 2013, 74:328-336.
74. Seubert P., et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992, 359:325-327.
75. Shankar G.M., et al. Isolation of low-n amyloid beta-protein oligomers from cultured cells, CSF, and brain. Methods Mol. Biol. 2011, 670:33-44.
76. Sperling R., et al. A randomized, double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with mild to moderate Alzheimer's disease who are apolipoprotein E ε4 carriers http://www2.kenes.com/efns/info/Documents/Sperling_Bapineuzumab%20IV%20Study%20302_EFNS%20Presentation%20Slides_9-11-2012.pdf.
77. Tabrizi M., et al. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J. 2010, 12:33-43.
78. Tucker S., et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J. Alzheimers Dis. 2015, 43:575-588.
79. Walsh D.M., Teplow D.B. Alzheimer's disease and the amyloid beta-protein. Prog. Mol. Biol. Transl. Sci. 2012, 107:101-124.
80. Weidemann A., et al. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell 1989, 57:115-126.
81. Weiner H.L., et al. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol. 2000, 48:567-579.
82. Wenk G.L. Assessment of spatial memory using the radial arm maze and Morris water maze. Curr. Protoc. Neurosci. 2004, 26. 8.5A:8.5A.1-8.5A.12 (Chapter 8, Unit 8 5A).
83. Wilcock D.M., et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci. 2004, 24:6144-6151.
84. Wilcock D.M., et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation 2004, 1:24.
85. Wilcock D.M., et al. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J. Neurosci. 2006, 26:5340-5346.
86. Wright A.L., et al. Neuroinflammation and neuronal loss precede Abeta plaque deposition in the hAPP-J20 mouse model of Alzheimer's disease. PLoS One 2013, 8:e59586.
87. Yamada K., et al. Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J. Neurosci. 2009, 29:11393-11398.
88. Yang T., et al. New ELISAs with high specificity for soluble oligomers of amyloid beta-protein detect natural Abeta oligomers in human brain but not CSF. Alzheimers Dement. 2013, 9:99-112.
89. Yang T., et al. A highly sensitive novel immunoassay specifically detects low levels of soluble Abeta oligomers in human cerebrospinal fluid. Alzheimers Res. Ther. 2015, 7:14.
90. Zago W., et al. Neutralization of soluble, synaptotoxic amyloid beta species by antibodies is epitope specific. J. Neurosci. 2012, 32:2696-2702.
91. Zhang Y., et al. Administration of amyloid-beta42 oligomer-specific monoclonal antibody improved memory performance in SAMP8 mice. J. Alzheimers Dis. 2011, 23:551-561.